Repatha (Evolocumab) and Finasteride: Drug Interaction Review

Why This Combination Gets Flagged

Patients prescribed Repatha for hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) are often men over 50. Many of these same patients take finasteride 1 mg for androgenetic alopecia or 5 mg for benign prostatic hyperplasia (BPH). The overlap in demographics, not pharmacology, is what drives the question. According to the FDA-approved Repatha prescribing information, evolocumab was studied alongside statins, ezetimibe, and other cardiovascular medications in trials enrolling over 30,000 patients, and no drug-drug interactions were identified [1]. The Repatha label does not list any contraindicated or cautioned co-medications.

Finasteride's FDA label similarly contains no warnings about monoclonal antibody co-administration [2]. Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) return no interaction flag when these two agents are cross-referenced. The absence of an interaction is not a gap in evidence. It reflects fundamental differences in how the body processes each drug.

Pharmacokinetic Analysis: No Overlapping Pathways

Evolocumab is a fully human IgG2 monoclonal antibody. Like all therapeutic antibodies, it is too large (approximately 144 kDa) to enter hepatocytes and interact with cytochrome P450 enzymes. Its elimination occurs through target-mediated disposition (binding to circulating PCSK9) and nonspecific proteolytic catabolism in the reticuloendothelial system [3]. It is not a substrate, inhibitor, or inducer of any CYP isoform. It does not interact with drug transporters such as P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or breast cancer resistance protein (BCRP).

Finasteride, by contrast, is a small molecule (molecular weight 372.5 Da) metabolized primarily by CYP3A4 with minor contribution from CYP3A5 [4]. Two inactive metabolites are produced: t-butyl side-chain monohydroxylated finasteride and monocarboxylic acid finasteride. Finasteride does not significantly inhibit or induce CYP enzymes at therapeutic doses. Its protein binding is approximately 90%, and it crosses the blood-brain barrier.

The pharmacokinetic verdict is straightforward. A monoclonal antibody that bypasses hepatic metabolism entirely cannot compete with, inhibit, or induce the CYP3A4 pathway that finasteride relies on. No alteration in the area under the curve (AUC), peak concentration (Cmax), or half-life of either drug is expected when they are given together. This conclusion aligns with the 2017 FDA guidance on therapeutic protein drug interactions, which states that monoclonal antibodies are generally exempt from traditional small-molecule DDI studies unless they modulate CYP-regulating cytokines [5].

Pharmacodynamic Assessment: Distinct Biological Targets

Evolocumab binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading hepatic LDL receptors. The result is increased LDL receptor density on hepatocyte surfaces and greater clearance of LDL cholesterol from plasma. In the FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced LDL-C by 59% and lowered the composite cardiovascular endpoint by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median 2.2 years of follow-up [6].

Finasteride inhibits type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in prostate tissue, scalp follicles, and liver. At 1 mg daily, finasteride reduces scalp DHT by approximately 64% and serum DHT by 71% without clinically significant effects on testosterone, cortisol, estradiol, or thyroid hormones at standard doses [7].

These two mechanisms share no common signaling cascade, receptor, enzyme, or feedback loop. PCSK9 is a serine protease involved in cholesterol homeostasis. 5-alpha reductase is a steroid metabolism enzyme. There is no known crosstalk between PCSK9-mediated LDL receptor recycling and androgen biosynthesis pathways.

Does Finasteride Affect Lipid Levels?

This secondary question matters because if finasteride meaningfully altered lipid parameters, it could theoretically modulate the clinical effect of evolocumab even without a direct molecular interaction. The data do not support that concern.

A prospective study published in the Journal of Clinical Endocrinology & Metabolism found that finasteride 5 mg daily for 12 months produced no significant changes in total cholesterol, LDL-C, HDL-C, or triglycerides in men with BPH [8]. A separate analysis from the Prostate Cancer Prevention Trial (PCPT, N=18,882) found no difference in cardiovascular event rates between finasteride and placebo groups, which is consistent with the absence of a meaningful lipid effect [9].

Some 5-alpha reductase inhibitors, including dutasteride, have shown small increases in total testosterone and estradiol due to substrate accumulation. These hormonal shifts are minor and do not translate into LDL-C changes that would interact with PCSK9 inhibitor therapy. Patients taking both drugs should expect their evolocumab-related LDL-C reduction to remain stable and unaffected by concurrent finasteride use.

Cardiovascular Safety of Finasteride in ASCVD Patients

Prescribers managing a patient on evolocumab for established ASCVD may reasonably ask whether finasteride carries independent cardiovascular risk. The available evidence is reassuring.

A 2019 meta-analysis published in the Journal of the American Heart Association examined cardiovascular outcomes associated with 5-alpha reductase inhibitors across multiple large cohorts [10]. The pooled analysis found no statistically significant increase in myocardial infarction, stroke, or cardiovascular mortality with finasteride use. The point estimates hovered near 1.0 for each endpoint. A Swedish population-based cohort study (N=80,875) similarly reported no increase in ischemic heart disease or heart failure events among finasteride users compared to matched controls [11].

The Endocrine Society's 2018 guidelines on testosterone therapy note that 5-alpha reductase inhibitors do not carry cardiovascular warnings and can be used in patients with pre-existing cardiovascular disease when clinically indicated [12]. For the patient on Repatha after a cardiac event, adding finasteride for hair loss or BPH does not introduce new cardiovascular risk.

Monitoring Recommendations When Using Both Drugs

No additional laboratory monitoring is required specifically because of the combination. Standard monitoring for each drug individually remains appropriate.

For evolocumab, the American College of Cardiology/American Heart Association (ACC/AHA) 2018 cholesterol guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiation and every 3 to 12 months thereafter to confirm LDL-C target achievement [13]. Liver function tests are not required because evolocumab does not undergo hepatic metabolism and has shown no hepatotoxicity signal in trials.

For finasteride, PSA monitoring requires awareness that the drug reduces PSA levels by approximately 50% within 6 months. Any PSA value in a patient on finasteride should be doubled for screening interpretation, per American Urological Association (AUA) guidelines [14]. Liver function testing is not routinely recommended for finasteride.

The combined monitoring schedule is simply the union of each drug's individual requirements: lipid panels per ACC/AHA cadence, PSA adjustment for finasteride effect, and standard clinical follow-up. There is nothing additive.

Administration and Practical Considerations

Evolocumab is administered as a subcutaneous injection (140 mg every 2 weeks or 420 mg monthly) using an autoinjector or prefilled syringe. Finasteride is taken orally once daily. There is no timing constraint between the two. They can be taken on the same day, at the same time, or on different schedules without concern.

Storage requirements differ: evolocumab requires refrigeration at 2-8°C (or room temperature up to 25°C for a maximum of 30 days), while finasteride tablets are stored at controlled room temperature. Patients managing both medications should keep the evolocumab autoinjector in the refrigerator and finasteride in a standard medicine cabinet.

For patients using the Repatha SureClick autoinjector or Pushtronex system alongside finasteride, no injection-site considerations change. Finasteride does not affect coagulation, platelet function, or subcutaneous tissue integrity in any way that would modify injection-site reactions.

When to Consult a Prescriber

While the combination itself is pharmacologically benign, patients should contact their prescriber if they experience any of the following, which relate to individual drug effects rather than an interaction:

Evolocumab-related: injection-site reactions (redness, pain, bruising occurring in approximately 5.7% of patients per the FOURIER safety data), upper respiratory symptoms, or new-onset muscle pain (myalgia was reported in 5.0% of evolocumab-treated patients vs. 4.8% on placebo) [6].

Finasteride-related: sexual side effects including decreased libido (reported in 1.8% vs. 1.3% placebo in the 1 mg hair-loss dose trials), erectile dysfunction (1.3% vs. 0.7%), or decreased ejaculate volume [7]. Breast tenderness or gynecomastia should also prompt evaluation.

Neither drug's side-effect profile is worsened by the other. A patient experiencing decreased libido on finasteride should not attribute this to Repatha, and vice versa. Clear attribution helps avoid unnecessary discontinuation of an effective cardiovascular therapy.

Population-Specific Notes

Older men (65+): Both drugs are commonly prescribed in this demographic. Evolocumab's pharmacokinetics are not significantly altered by age. Finasteride's half-life extends from approximately 6 hours in younger men to roughly 8 hours in men over 70, but this does not create any interaction concern [2].

Patients with hepatic impairment: Evolocumab is not hepatically metabolized, so hepatic impairment has no effect on its clearance. Finasteride is hepatically metabolized, and its use has not been studied in patients with hepatic impairment. The FDA label recommends caution in this population [2]. This caution is specific to finasteride alone and is unrelated to Repatha co-administration.

Patients on statin therapy: Many evolocumab patients also take a statin. Statins are CYP3A4 substrates (atorvastatin, lovastatin, simvastatin) or CYP2C9 substrates (rosuvastatin, fluvastatin). Finasteride's CYP3A4 metabolism raises a theoretical question about statin-finasteride interaction, but finasteride is not a CYP3A4 inhibitor at clinical doses and does not affect statin pharmacokinetics [4]. The three-drug combination of a statin, evolocumab, and finasteride carries no layered interaction risk.